ArticleBMC pediatrics2026
Integrating genome and RNA sequencing to enhance diagnostic precision in cerebral palsy.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundCerebral palsy (CP), a group of permanent disorders of the development of movement and posture affecting developing fetal or infant brain, shows considerable genetic diversity. Genetic diagnosis is not yet the first-tier diagnostic test for CP. This study aimed to diagnose patients with CP and explore novel diagnostic strategies.
methodsThis study cohort comprised 27 children diagnosed with CP and their asymptomatic parents. Whole-Genome Sequencing and RNA sequencing were employed for genetic diagnostics in these children. The R package Gene Set Variation Analysis was employed to evaluate the pathway enrichment variations between the samples.
resultsFamily-based Whole-Genome Sequencing diagnostics identified pathogenic or likely pathogenic variants in 2 children and variants of uncertain significance in 7 children. A total of 216 genes with damaging de novo variant were found, including 3 genes previously associated to CP: PROC, WDR81, and SPTBN2. Additionally, 22 genes contained two or more damaging de novo variants. RNA-seq analysis revealed 5 candidate genes with abnormal expression and 250 candidate events with abnormal alternative splicing. Notably, highly reliable alternative splicing sites were found in DNMT1 and VPS13C. Furthermore, pathway analysis identified aberrant pathways that may help determine the underlying cause. This approach uncovered 3 abnormal pathways related to neurological functions in 2 children and a deleterious de novo variant in the S1PR4 gene.
conclusionsThese findings supported the application of genetic diagnostics in CP and suggested that a combined approach using genomics and transcriptomics is more comprehensive and reliable. Therefore, we advocated for genetic diagnostics as the first-tier diagnostic test for CP, which not only aids in understanding the etiology but also provides a basis for subsequent treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.